LRIG inhibitors of growth factor signalling - double-edged swords in human cancer?

European Journal of Cancer

Volumn 43, Issue 4, 2007, Pages 676-682

  Hedman, Håkan ^a   Henriksson, Roger ^a,b  

^a UMEÅ UNIVERSITY   (Sweden)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

EGFR; ErbB; LRIG; Receptor tyrosine kinase; Tumour suppressor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LEUCINE RICH REPEAT AND IMMUNOGLOBULIN LIKE DOMAIN PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER; CELL PROLIFERATION; DEGRADATION; HOMEOSTASIS; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SKIN; STEM CELL; UBIQUITINATION;

CELL COMMUNICATION; CELL PROLIFERATION; FORECASTING; HOMEOSTASIS; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; STEM CELLS;

EID: 33947651745     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.10.021     Document Type: Article

References (46)

1. Suzuki Y., Sato N., Tohyama M., et al. cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain. LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains. J Biol Chem 271 (1996) 22522-22527
2. Nilsson J., Vallbo C., Guo D., et al. Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun 284 (2001) 1155-1161
3. Holmlund C., Nilsson J., Guo D., et al. Characterization and tissue-specific expression of human LRIG2. Gene 332 (2004) 35-43
4. Guo D., Holmlund C., Henriksson R., et al. The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues, and a homolog in Ascidiacea. Genomics 84 (2004) 157-165
5. Gur G., Rubin C., Katz M., et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 23 (2004) 3270-3281
6. Laederich M.B., Funes-Duran M., Yen L., et al. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 279 (2004) 47050-47056
7. Goldoni S, Iozzo RA, Kay P, et al. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 2006; doi:10.1038/sj.onc.1209803.
8. Hedman H., Nilsson J., Guo D., et al. Is LRIG1 a tumour suppressor gene at chromosome 3p14.3?. Acta Oncol 41 (2002) 352-354
9. Thomasson M., Hedman H., Guo D., et al. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT-PCR and immunohistochemical analysis. Br J Cancer 89 (2003) 1285-1289
10. Tanemura A., Nagasawa T., Inui S., et al. LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg 31 (2005) 423-430
11. Suzuki Y., Miura H., Tanemura A., et al. Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia. FEBS Lett 521 (2002) 67-71
12. Nilsson J., Starefeldt A., Henriksson R., et al. LRIG1 protein in human cells and tissues. Cell Tissue Res 312 (2003) 65-71
13. Musacchio M., and Perrimon N. The Drosophila kekkon genes: novel members of both the leucine-rich repeat and immunoglobulin superfamilies expressed in the CNS. Dev Biol 178 (1996) 63-76
14. Krusius T., and Ruoslahti E. Primary structure of an extracellular matrix proteoglycan core protein deduced from cloned cDNA. Proc Natl Acad Sci USA 83 (1986) 7683-7687
15. Ghiglione C., Carraway III K.L., Amundadottir L.T., et al. The transmembrane molecule kekkon 1 acts in a feedback loop to negatively regulate the activity of the Drosophila EGF receptor during oogenesis. Cell 96 (1999) 847-856
16. Ghiglione C., Amundadottir L., Andresdottir M., et al. Mechanism of inhibition of the Drosophila and mammalian EGF receptors by the transmembrane protein Kekkon 1. Development 130 (2003) 4483-4493
17. Moscatello D.K., Santra M., Mann D.M., et al. Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest 101 (1998) 406-412
18. Iozzo R.V., Moscatello D.K., McQuillan D.J., et al. Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 274 (1999) 4489-4492
19. Zhu J.X., Goldoni S., Bix G., et al. Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J Biol Chem 280 (2005) 32468-32479
20. Jensen K.B., and Watt F.M. Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence. Proc Natl Acad Sci USA 103 (2006) 11958-11963
21. Yang W.M., Yan Z.J., Ye Z.Q., and Guo D.S. LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87. BJU Int 98 (2006) 898-902
22. Rubin C., Gur G., and Yarden Y. Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Res 15 (2005) 66-71
23. Vassar R., and Fuchs E. Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentiation. Genes Dev 5 (1991) 714-727
24. Cook P.W., Piepkorn M., Clegg C.H., et al. Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J Clin Invest 100 (1997) 2286-2294
25. Shimizu T., Izumi H., Oga A., et al. Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology 202 (2001) 203-206
26. Budiyanto A., Bito T., Kunisada M., et al. Inhibition of the epidermal growth factor receptor suppresses telomerase activity in HSC-1 human cutaneous squamous cell carcinoma cells. J Invest Dermatol 121 (2003) 1088-1094
27. Salomon D.S., Brandt R., Ciardiello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 (1995) 183-232
28. Citri A., and Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7 (2006) 505-516
29. Ljuslinder I., Malmer B., Golovleva I., et al. Increased copy number at 3p14 in breast cancer. Breast Cancer Res 7 (2005) R719-R727
30. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
31. Gill G.N., and Lazar C.S. Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells. Nature 293 (1981) 305-307
32. Barnes D.W. Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture. J Cell Biol 93 (1982) 1-4
33. Gulli L.F., Palmer K.C., Chen Y.Q., et al. Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity. Cell Growth Differ 7 (1996) 173-178
34. Gullick W.J. c-erbB-4/HER4: friend or foe?. J Pathol 200 (2003) 279-281
35. Jones F.E., Welte T., Fu X.Y., et al. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation. J Cell Biol 147 (1999) 77-88
36. Sartor C.I., Zhou H., Kozlowska E., et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 21 (2001) 4265-4275
37. Witton C.J., Reeves J.R., Going J.J., et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200 (2003) 290-297
38. Williams E.E., Trout L.J., Gallo R.M., et al. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Lett 192 (2003) 67-74
39. Thomasson M., Hedman H., Junttila T.T., et al. ErbB4 is downregulated in renal cell carcinoma: a quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family. Acta Oncol 43 (2004) 453-459
40. Guo D., Nilsson J., Haapasalo H., et al. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol 111 (2006) 238-246
41. Febbo P.G., Lowenberg M., Thorner A.R., et al. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J Urol 173 (2005) 1772-1777
42. Kauraniemi P., Bärlund M., Monni O., et al. New amplified and highly expressed genes discovered in the ERBB2 amplicon in breast cancer by cDNA microarrays. Cancer Res 61 (2001) 8235-8240
43. Welsh J.B., Sapinoso L.M., Su A.I., et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61 (2001) 5974-5978
44. Lapointe J., Li C., Higgins J.P., et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101 (2004) 811-816
45. Bhattacharjee A., Richards W.G., Staunton J., et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98 (2001) 13790-13795
46. Rhodes D.R., Yu J., Shanker K., et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6 (2004) 1-6